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ABSTRACT
Background Patients with non-demented Parkinson’s 
disease (PD) sometime have mild cognitive impairment 
(MCI), and mild cognitive impairment in Parkinson’s 
disease (PD-MCI) may convert to Parkinson’s disease 
with dementia (PDD) within several years. Cognitive 
impairment also occurs in the early stages of the dis-
ease, gradually progressing to lower quality of life and 
instrumental activities of daily living. It is important to 
elucidate the predictors of progression from PD-MCI to 
PDD via longitudinal studies.
Methods This was a single center, case-control study. 
We analysed data from 49 patients with PD-MCI diag-
nosed as level I using the Movement Disorder Society 
PD-MCI criteria at baseline who had completed 1.5 
years of follow-up. We defined patients who progressed 
to PDD as patients with progressive PD-MCI and 
patients who did not progress to PDD as patients with 
non-progressive PD-MCI. Depression, apathy, sleep dis-
orders, constipation, light-headedness, hallucinations, 
impulse control disorders (ICDs) and impulsive–com-
pulsive behaviors (ICBs) at baseline were statistically 
analysed as predictors of progression.
Results Of the 49 PD-MCI patients, 33 did not 
convert to PDD (non-progressive PD-MCI), and 16 con-
verted to PDD (progressive PD-MCI). The Mini-Mental 
State Examination (MMSE) score, light-headedness 
and ICDs were elucidated as predictors of progressive 
PD-MCI via a multivariate logistic regression model. 
The adjusted odds ratios (ORs) and 95% confidence 
intervals (CIs) for each item were MMSE score, OR 
0.324, 95% CI 0.119–0.882, P = 0.027; light-headedness, 
OR 27.665, 95% CI 2.263–338.185, P= 0.009; and ICDs, 
OR 53.451, 95% CI 2.298–291.085, P = 0.010.
Conclusion Cognitive function, ICDs and light-
headedness may be risk factors for the development of 
PDD in PD-MCI patients.
Key words cognition; dementia; impulse control dis-
orders; light-headedness; Parkinson’s disease
Patients with Parkinson’s disease (PD) have progressive 
motor symptoms such as muscle rigidity, tremor, loss 
of postural reflex, akinesia and bradykinesia caused by 
neurodegeneration of dopaminergic neurons of the sub-
stantia nigra and striatum. The definition of the disease 
was based on these motor symptoms,1 but it has been 
found that various non-motor symptoms, such as auto-
nomic neuropathy (constipation, orthostatic hypoten-
sion, dysuria, sweating disorder and others), psychiatric 
symptoms (depression, apathy and hallucinations), sleep 
disorders, behavioral abnormalities [impulse control 
disorders (ICDs)] and cognitive impairment, can be 
complicated. The cognitive impairment of PD is thought 
to be due to cerebrovascular pathology, Alzheimer’s dis-
ease pathology, Lewy body pathology that characterizes 
pathology of PD and a number of other mechanisms.2 In 
recent years, Lewy body pathology based on the Braak 
hypothesis is considered to be the main pathology of 
cognitive impairment of PD.2 Braak proposed that Lewy 
body development would first ascend the brainstem to 
the midbrain and substantia nigra and eventually dam-
age the cerebral cortex.3, 4 This hypothesis is broadly 
accepted. The Meynert basal ganglia, amygdala, and 
cerebral cortex are thought to be the focus of cognitive 
impairment of PD, but there are still many unclear 
cases. A disease concept of Parkinson’s disease with 
dementia (PDD) has been proposed and investigated. A 
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systematic review reports the point prevalence of PDD 
is about 30%.5 There is also a report that the prevalence 
of dementia rate is 83% at 20 years after the onset of 
PD.6 Initially, it was believed that cognitive impairment 
occurred during the advanced stages of PD.7 However, 
it has been found that many patients have cognitive 
impairment from the first diagnosis of PD. The concept 
of mild cognitive impairment in PD (PD-MCI) has 
been proposed as a prodromal stage of PDD. However, 
each researcher had different definitions of PD-MCI.8 
Recently, a clinical diagnostic criteria for PD-MCI has 
been classified.9 PD-MCI is evident in 10–20% patients 
at the time of PD diagnosis.6 Among PD patients 
without dementia approximately 25–30% are PD-MCI.6 
PD-MCI is suggested to be an identical risk factor for 
developing to PDD.10 However, the predictive factors 
for the progression from PD-MCI to PDD have not been 
well analysed. In this study, to elucidate the predictors 
for progression from PD-MCI to PDD, we compared the 
motor and non-motor symptoms between progression 
and non-progression groups of PD-MCI to PDD.
MATERIALS AND METHODS
We conducted a case-control study within a cohort to 
investigate the predictors of progression. The observa-
tion period was from 2012 to 2016.
Patient Data
Patients with PD who were treated at Tottori University 
Hospital were included in this study. At baseline, PDD 
and normal cognitive patients were excluded.
We performed the Mini-Mental State Examination 
(MMSE) and Japanese version of the Montreal 
Cognitive Assessment (MoCA-J) for neuropsychologi-
cal evaluation. At the initial diagnosis of PD-MCI, 
in addition to neuropsychological examinations, we 
evaluated the motor part of the Unified Parkinson’s 
Disease Rating Scale (UPDRS-III) as motor symptoms 
and asked the patients themselves and their caregivers 
or family members to respond to awareness of the non-
motor symptoms by filling in questionnaires. We chose 
the following as items of non-motor symptoms: depres-
sion by the Geriatric Depression Scale (GDS) and the 
Apathy Scale,11 sleep abnormalities by the Pittsburgh 
Sleep Quality Index (PSQI) and the Epworth Sleepiness 
Scale (ESS),12 rapid eye movement sleep behavior 
disorder (RBD) by the RBD screening questionnaire 
[Japanese version] (RBDSQ-J),13 awareness of consti-
pation, awareness of head rush (light-headedness) as 
orthostatic hypotension, awareness of hallucinations, 
impulse control disorders (ICDs) [pathological gambling 
(gambling), excessive sexuality (hypersexuality), com-
pulsive shopping (shopping) and binge eating (eating)] 
and impulsive–compulsive behaviors (ICBs) [hobbyism, 
repetition of the same simple behavior (punding) and 
excessive craving for dopamine drug use (dopamine 
dysregulation syndrome: DDS)] by the Questionnaire 
for Impulsive–Compulsive Disorders (QUIP).14 In 
QUIP, one or two questions are prepared for each ICDs 
and ICBs item, and if one is checked, the diagnosis is 
made.
Demographic information included sex, age at 
disease onset, age at first examination, disease duration, 
years of education and total L-dopa equivalent doses 
(total LEDs).
The diagnosis of PD was made according to the 
diagnostic criteria of the UK Brain Bank.15 Patients 
with PDD were identified according to the Movement 
Disorder Society (MDS) diagnostic criteria of 2007.16, 17 
Among non-PDD patients, patients with PD-MCI were 
identified according to the MDS criteria of 2012.9, 17 
PD-MCI level I criteria was applied for this research.18
We identified patients with PD-MCI among pa-
tients with PD. After an observation period of 1.5 years, 
we again classified their cognitive diagnosis according 
to the same diagnostic criteria.
When the PD-MCI group was observed over time, 
a group proceeding to PDD (PD-MCI converter), a 
group in the state of PD-MCI (PD-MCI stable) and a 
group returning to normal cognition (PD-MCI reverter) 
were identified. We defined the PD-MCI converter 
group as progressive PD-MCI, and defined PD-MCI 
stable group and the PD-MCI reverter group as non-
progressive PD-MCI (Fig. 1).
Statistical Analysis
The relative risk of progression from PD-MCI to PDD 
was estimated as odds ratio (OR) using logistic regres-
sion models. First, the difference between the two 
groups was analyzed via Student’s t-test for normally 
distributed variables, the Mann–Whitney U test for non-
parametric data and the chi-square test for comparison 
of frequencies. Next, variables that differed between 
the two groups at P < 0.1 by bivariate analysis were 
selected. Pearson’s and Spearman’s correlation coeffi-
cients between the independent variables of the selected 
items were calculated and judged whether or not they 
were suitable candidates for logistic regression analysis. 
Selected items were incorporated in the logistic regres-
sion models. ORs were calculated in bivariate regres-
sion models and a multivariate regression model. In a 
multivariate logistic regression model, suitable predictor 
variables were selected using a backward likelihood ra-
tio test to avoid arbitrary judgment. The fitness of these 
models was evaluated using the Hosmer–Lemeshow 
method. P values less than 0.05 were considered to 
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indicate statistical significance. Data analysis was con-
ducted using IBM SPSS for Windows, version 22.
Ethical Approval
The study was conducted in accordance with the current 
revision of the Declaration of Helsinki and applicable 
national laws and regulations. It was approved by the 
Medical Ethics Committee of Tottori University (ap-
proval number 2178).
RESULTS
We identified 49 patients diagnosed with PD-MCI dur-
ing the observation period for whom follow-up surveil-
lance could be conducted. Of the 49 PD-MCI patients, 
16 patients converted to PDD (progressive PD-MCI), 
20 patients remained in PD-MCI (stable PD-MCI) and 
13 patients reverted to normal cognitive level (reverted 
PD-MCI). We defined the reverted and stable PD-MCI 
groups (33 patients) as the non-progressive PD-MCI 
group (Fig. 1). No patients used anticholinergic drugs 
or anti-dementia drugs (donepezil, rivastigmine, galan-
tamine or memantine) during the observation period.
There were no missing data for sex, age at disease 
onset, age at first examination, disease duration, years 
of education, MoCA-J, MMSE, GDS, Apathy Scale, 
RBDSQ-J, constipation, light-headedness, hallucina-
tions, ICDs and ICBs. Data were missing for 1 patient 
for total LEDs, 24 patients for UPDRS-III score and 2 
patients for PSQI and ESS.
In bivariate analysis, MMSE, ESS, light-headed-
ness, ICDs, gambling, hypersexuality, shopping and 
DDS were selected at P < 0.1 (Table 1). The absolute 
values of the Pearson and the Spearman correlation 
coefficient between the independent variables of the 
selected items were less than 0.7, and all items were 
incorporated as candidates for the logistic regression 
model. Using these eight items, ORs were calculated 
using bivariate logistic models and multivariate logistic 
models.
The bivariate logistic models showed that light-
headedness, gambling, hypersexuality and ICDs were 
statistically significant as predictors of progressive 
PD-MCI at P < 0.05 (Table 2). The OR for light-
headedness was 4.776 (95% CI 1.310–17.402), the OR 
for gambling was 7.045 (95% CI 1.190–41.705), the OR 
for hypersexuality was 14.545 (95% CI 1.527–138.511) 
and the OR for ICDs was 4.500 (95% CI 1.202–16.848).
The multivariate logistic regression models 
showed that MMSE, light-headedness and ICDs were 
selected as variables of the model. Age, sex and years of 
Fig. 1. Cognitive progression of PD-MCI. The number of PD-MCI patients at baseline (n = 49) and the numbers of PD-NC, PD-MCI 
and PDD patients after 1.5 years. The Movement Disorder Society (MDS) diagnostic criteria were used to diagnose cognitive function 
status. PD-NC, PD patients with normal cognition.
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education were also adjusted. The Hosmer–Lemeshow 
chi-square value was 0.338, suggesting a good fit of the 
model. The discriminant predictive value was 75.6%, 
and the model was effective for prediction. There were 
no outliers with predicted values exceeding 3 SD. In the 
multivariate logistic regression model, the adjusted ORs 
for each item were as follows: MMSE score (OR 0.324, 
95% CI 0.119–0.882, P = 0.027), light-headedness (OR 
27.665, 95% CI 2.263–338.185, P = 0.009) and ICDs (OR 
53.431, 95% CI 2.298–291.085, P = 0.010).
DISCUSSION
The present study identified not only the MMSE score 
of the cognitive scale, but also light-headedness and 
ICDs as risk factors for progression from PD-MCI to 
PDD by using multiple logistic regression analysis. 
Although, many studies regarding the risk for progres-
sion from non-PDD to PDD have been reported, a few 
studies have reported the risk for progression from 
PD-MCI to PDD. In previous papers, cognitive func-
tions such as visuospatial, semantic language, episodic 
memory and mental flexibility were reported to relate 
with the progression of PDD.19, 20 To our knowledge, 
this is the first report that light-headedness and ICDs are 
risk factors for converting from PD-MCI to PDD.
Light-headedness
Autonomic nervous system disorders cause orthostatic 






*P < 0.1 
**P < 0.05Characteristic n = 49 n = 33 n = 16
Sex (male: female) 24:25 15:18 9:7 0.478
Age at disease onset (years) mean (SD) 60.63 (11.0) 60.42 (11.1) 61.06 (11.3) 0.852
Age at first examination (years) mean (SD) 70.31 (7.9) 70.03 (7.8) 70.88 (8.2) 0.729
Disease duration (years) mean (SD) 9.20 (7.6) 9.12 (8.1) 9.38 (6.6) 0.914
Education (years) mean (SD) 12.49 (2.8) 12.55 (3.1) 12.3 (2.3) 0.845
Total LEDs (mg) mean (SD) 467.4 (319.9) 420.8 (284.2) 570.1 (377.5) 0.135
UPDRS-III score (points) median (IQR) 21.96 (17.00–27.50) 21.05 (15.00–27.75) 25.60 (22.00–29.50) 0.394
MMSE (points) median (IQR) 27.57 (26.00–29.00) 27.85 (27.00–29.00) 27.00 (26.00–28.00) 0.073 *
GDS (points) median (IQR) 5.41 (2.00–7.50) 4.97 (1.00–8.00) 6.31 (4.00–7.75) 0.151
Apathy Scale (points) median (IQR) 15.73 (11.50–19.00) 15.33 (11.50–19.50) 16.56 (11.00–19.00) 0.528
PSQI (points) median (IQR) 6.32 (3.00–9.00) 5.91 (3.00–8.75) 7.20 (4.00–10.00) 0.281
ESS (points) median (IQR) 7.04 (4.00–10.00) 6.34 (3.00–9.75) 8.53 (4.00–12.00) 0.075*
RBDSQ (points) median (IQR) 4.29 (1.50–6.00) 3.82 (1.00–5.50) 5.25 (2.00–7.75) 0.127
Constipation n (%) 38 (77.6%) 24 (72.7%) 14 (87.5%) 0.216
Light- headedness n (%) 16 (32.7%) 7 (21.2%) 9 (56.3%) 0.014**
Hallucinations n (%) 9 (18.4%) 5 (15.2%) 4 (25.0%) 0.322
ICD & ICB n (%) 21 (42.9%) 12 (36.4%) 9 (56.3%) 0.187
ICD n (%) 13 (26.5%) 5 (15.2%) 8 (50.0%) 0.014**
 Gambling n (%) 7 (14.3%) 2 (6.1%) 5 (31.3%) 0.030**
 Hypersexuality n (%) 6 (12.2%) 1 (3.0%) 5 (31.3%) 0.011**
 Shopping n (%) 4 (8.2%) 1 (3.0%) 3 (18.8%) 0.096*
 Eating n (%) 7 (14.3%) 3 (9.1%) 4 (25.0%) 0.146
ICB n (%) 12 (25.0%) 8 (28.1%) 4 (25.0%) 0.608
 Hobbyism n (%) 6 (12.2%) 3 (9.1%) 3 (18.8%) 0.298
 Punding n (%) 6 (12.2%) 4 (12.1%) 2 (12.5%) 0.649
 DDS n (%) 6 (12.2%) 2 (6.1%) 4 (25.0%) 0.080*
Statistical analysis was performed as follows: chi-square test for sex, constipation, light-headedness, hallucinations, gambling, hyper-
sexuality, shopping, eating, hobbyism, punding and DDS. T-test for age at onset, age at examination, disease duration, education and 
total LEDs. Mann–Whitney U test for USDRS-IIIscore, MMSE, GDS, Apathy Scale, PSQI, ESS and RBDSQ. IQR, Interquartile range.
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hypotension in PD patients. When orthostatic hypoten-
sion develops, the patient feels light-headedness as a 
subjective symptom. Orthostatic hypotension has been 
reported to be a risk factor for cognitive dysfunction in 
PD (non-PDD to PDD),21, 22 but there has been no report 
of light-headedness as a risk factor. Our results may 
support the hypothesis that orthostatic hypotension is 
a risk factor for progression of cognitive impairment in 
PD. However, our study did not evaluate the patients’ 
blood pressure and did not accurately refer to the 
relationship between light-headedness and orthostatic 
hypotension. It is necessary to study the relationship 
between light-headedness and orthostatic hypotension. 
Light-headedness may be related to factors other than 
orthostatic hypotension, including brain blood flow 
insufficiency due to arterial sclerosis such as the basilar 
artery or carotid artery. Light-headedness may be a 
useful question in clinical practice because the risk of 
progression can be easily confirmed without tests of 
orthostatic hypotension only by asking the PD-MCI 
patient whether light-headedness exists or not.
ICDs
The association between ICDs and cognitive function in 
Parkinson’s disease is complex. A meta-analysis study 
has shown that patients with ICDs have impaired set-
shifting and reward-related decision-making abilities.23 
There is another study that has compared cognitive 
domains according to with or without ICDs in patients 
with PD-NC, PD-MCI and PDD. In this study, there 
was no significant difference in the cognitive function 
of the PD-NC with or without ICDs group; however, 
the PD-MCI with ICDs group had impaired atten-
tion domain than the PD-MCI without ICDs group. 
Furthermore, the PDD with ICDs group showed poorer 
performance in the executive domain than the PDD 
without ICDs group.24 In addition, this study reported 
that in patients with PD-MCI as well as PDD patients 
with ICDs, frontal-striatal dysfunction (i.e., executive 
and attentive) may be more severe than posterior dys-
function (i.e., language and visuospatial).24 However, 
these reports about the relationship between PD-MCI 
and ICDs are all small cross-sectional studies with 
different results from study to study. There are still 
many unknowns. The present study is a valuable report 
that ICDs are associated with longitudinal PD-MCI 
cognitive progression. PD-MCI with ICDs have frontal 
dysfunction and may be suggesting pathological 
progression in the cerebral cortex and may be more 
likely to progress to PDD. It seems to fit Braak’s model 
of development of Parkinson’s disease pathology.3, 4 
Further studies, including longitudinal morphological 
and functional imaging and biological markers, may be 
necessary to clarify the question.
One limitation of this research is that it was a small 
and single center cohort study because there were few 
patients with PD-MCI whose cognitive function could 
be assessed longitudinally. In the future, longitudinal 
studies should be performed with more PD-MCI 
patients for more generalised information. Another 
limitation is that the PD-MCI diagnostic criteria were 
the level I criteria. Level II criteria9 might reveal more 
detailed features of the cognitive function of patients 
with progressive PD-MCI. The final limitation is the 
lack of drug information on amantadine that may affect 
cognitive function, and dopamine agonists that can be 
a risk for ICDs. These drug data should be reflected in 
future studies.
In conclusion, if a patient with PD-MCI has ICDs 
and light-headedness, then there is a risk of progression 
to PDD, and these symptoms should be considered in 
clinical practice.
Table 2. Relative risk of progression from PD-MCI to PDD
Bivariate odds ratios Multivariate-adjusted odds ratios
ORs 95% CI P ORs 95% CI P
MMSE 0.651 0.412–1.028 0.065 0.324 0.119–0.882 0.027
ESS 1.096 0.965–1.245 0.159 – – –
Light-headedness 4.776 1.310–17.402 0.018 27.665 2.263–338.185 0.009
Gambling 7.045 1.190–41.705 0.031 – – –
Hypersexuality 14.545 1.527–138.511 0.020 – – –
Shopping 7.385 0.702–77.679 0.096 – – –
DDS 5.167 0.834–32.000 0.078 – – –
ICDs 4.500 1.202–16.848 0.026 53.451 2.298–291.085 0.010
Bivariate odds ratios were calculated using bivariate logistic regression models. Multivariate odds ratios were calculated using multivar-
iate logistic regression models with adjustment for age, sex and years of education. To identify suitable predictable variables, predictable 
variables were selected using a backward likelihood ratio test.
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